The RIG-I like receptors (RLRs) are intracellular enzyme sentries that detect viral infection and initiate a first line of antiviral defense. The cellular molecules that activate RLRs in vivo are not clear.
Dec 14, 2018
0
64
The selection of a first-line chemotherapy drug to treat many types of cancer is often a clear-cut decision governed by standard-of-care protocols, but what drug should be used next if the first one fails?
Nov 7, 2018
0
90
Scientists from Hokkaido University have discovered a novel defensive response to SARS-CoV-2 that involves the viral pattern recognition receptor RIG-I. Upregulating expression of this protein could strengthen the immune ...
May 21, 2021
0
63
Acute porphyria is a group of uncommon diseases that can cause severe, potentially life-threatening attacks of abdominal pain, nausea, vomiting and paralysis. Liver transplantation is currently the only effective treatment ...
Feb 7, 2019
0
7
While many scientists are working on developing a coronavirus vaccine, others are busy testing antiviral drugs.
Mar 30, 2020
0
7
A new research result from Aarhus University shows that a so-called circular RNA molecule, which has been designated as carcinogenic, is actually not found in cancer cells. The results have just been published in Nature Communications.
Sep 24, 2020
0
210
New research describes how highly proliferative leukemia cells end up becoming normal cells that no longer multiply, by changing the chemical modifications—the so-called epigenetics—of a type of its genetic material: ...
Jun 9, 2022
0
10
COVID patients exhale high numbers of virus during the first eight days after symptoms start, as high as 1,000 copies per minute, reports a new Northwestern Medicine study.
Sep 11, 2023
1
3
Survival has improved greatly in children with acute lymphocytic leukemia (ALL). But a certain form of ALL that occurs mostly in babies is still very lethal, with a survival rate below 50 percent: B-cell acute lymphoblastic ...
Jun 1, 2022
0
35
A human genetic mechanism hijacked by SARS-CoV-2, the coronavirus behind the COVID-19 pandemic, to help it spread also makes it vulnerable to a new class of drug candidates, a new study finds.
Jun 24, 2021
0
21
